Roche Proposes to buy Full Stake in Genentech - Interview With
Chairman

LONDON, July 21, 2008 /PRNewswire-FirstCall/ -- Roche, the
healthcare company, announced today that it has proposed to acquire
the outstanding publicly held interest in biotech company Genentech
for US$89.00 per share in cash, or a total payment of approximately
US$43.7bn to equity holders of Genentech other than Roche. Roche
acquired a majority in Genentech in 1990 and currently owns 55.9%
of all outstanding shares.

In a video interview Franz Humer, Roche Chairman, said the two
companies had collaborated for over 20 years but it was time to put
the partnership "on a new level".

"We are absolutely convinced that it is in the interest of both
parties that we acquire the 100 per cent and then structure it in a
way that strengthens both sides of the operation."

In the interview Mr Humer looks at how the offer will impact the
group structurally and financially and what it means for employees
as well as doctors and patients around the world.

It's free to view. All you need to do is register at http://www.cantos.com.
Cantos.com, the online financial broadcaster, features in-depth
interviews, documentaries and webcasts with senior company
executives. If you would like to contact us, please email or phone
+44-207-936-1333. enquiries@cantos.com

CONTACT: If you would like to contact us, please email or phone
+44-207-936-1333 enquiries@cantos.com